FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
about
Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.FcγR requirements leading to successful immunotherapy.Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis.
P2860
Q35933551-4499F5C5-40DE-4F42-B401-FE213E1F59F4Q36055257-0A8FCF55-1E19-442D-8772-76952C29D77BQ36115580-954C79C4-D762-4DA9-81FA-DBEF9CAE2369Q36413979-F6880ED0-990C-452F-9938-6F2A6390CF1AQ37685527-8352C4FF-89B9-4A5B-90FB-B777CC8DB5F2Q38383212-2E207EAD-3B63-43D3-A473-9921E016B6ACQ38615360-EAC95492-EFE3-40D5-80CD-4BFB60D6287FQ39023377-3F2EA11C-1F03-4171-8F76-076843EF1CA7Q39154047-2CD237B0-0144-43B3-9E00-AB45D20F6042
P2860
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
FCGR2A and FCGR3A polymorphism ...... and oxaliplatin +/- cetuximab.
@ast
FCGR2A and FCGR3A polymorphism ...... and oxaliplatin +/- cetuximab.
@en
type
label
FCGR2A and FCGR3A polymorphism ...... and oxaliplatin +/- cetuximab.
@ast
FCGR2A and FCGR3A polymorphism ...... and oxaliplatin +/- cetuximab.
@en
prefLabel
FCGR2A and FCGR3A polymorphism ...... and oxaliplatin +/- cetuximab.
@ast
FCGR2A and FCGR3A polymorphism ...... and oxaliplatin +/- cetuximab.
@en
P2093
P2860
P356
P1433
P1476
FCGR2A and FCGR3A polymorphism ...... and oxaliplatin +/- cetuximab.
@en
P2093
Astrid M Dalsgaard
Christian Kersten
Elin H Kure
Eva Skovlund
Janne B Kjersem
Kjell M Tveit
Mette K Yilmaz
Tone Fokstuen
Tone Ikdahl
Tormod Guren
P2860
P2888
P356
10.1186/1471-2407-14-340
P407
P577
2014-05-19T00:00:00Z
P5875
P6179
1024746434